人类乳头状病毒检测诊断宫颈癌前病变的价值：随机对照研究的系统评价_《中国循证医学杂志》

作者：

李克敏 ¹ ,  尹如铁 ¹ , 康德英 ² , 伍伟伟 ³ , 文进 ²

1. 四川大学华西第二医院妇科（成都?610041）；2. 四川大学华西临床医学院循证医学与临床流行病学教研室（成都?610041）；3. 四川大学华西第二医院病理科（成都?610041）;

关键词：

宫颈癌前病变人类乳头状病毒系统评价 Meta分析随机对照试验

DOI：

10.7507/1672-2531.20110154

视频：

导出 下载 收藏 扫码 引用

摘要 全文 图表 视频 参考文献 施引文献 补充材料

目的　系统评价人类乳头状病毒检测对宫颈癌前病变的诊断价值。
方法　计算机检索CBM、CNKI、MEDLINE、PubMed、EMbase（均从建库至2010年6月），Cochrane临床对照试验中心注册库（2010年第2期），并手工检索相关杂志和纳入研究的参考文献。由两位评价员按照纳入与排除标准独立选择文献、提取资料和评价质量后，采用Meta Disc 1.4软件进行Meta分析，并用RevMan 5.0软件绘制森林图和SROC曲线。
结果　共纳入7个随机对照研究，合计171 604例受试者。Meta分析结果显示：与传统的宫颈细胞学检查比较，人类乳头状病毒（HPV）检测能明显提高对宫颈癌前病变诊断的敏感性，其中HPV联合宫颈细胞学筛查诊断宫颈上皮内瘤变2级及以上病变时，与传统的宫颈细胞学检查比较差异有统计学意义（P lt;0.000 01）；但HPV检测却明显降低了对其诊断的特异性；只检测HPV，同时检测HPV和宫颈细胞学和先检测HPV。再以细胞学分流的方法诊断宫颈上皮内瘤变，与传统宫颈细胞学检查比较，除了第三种方法诊断宫颈上皮内瘤变1级及以上病变无统计学差异外（P=0.41），其余两种方法与之比较均有明显的统计学差异（P lt;0.01）。
结论　现有循证医学证据显示，与传统的宫颈细胞学筛查相比，HPV检测联合宫颈细胞学筛查可以明显提高诊断宫颈上皮内瘤变2级及以上病变的敏感性，但HPV检测并不能提高诊断宫颈癌前病变的特异性；应用HPV检测筛查宫颈癌前病变有待进一步研究。

引用本文： 李克敏,尹如铁,康德英,伍伟伟,文进. 人类乳头状病毒检测诊断宫颈癌前病变的价值：随机对照研究的系统评价. 中国循证医学杂志, 2011, 11(8): 910-918. doi: 10.7507/1672-2531.20110154 复制

1.	1 Reeves WC, Quiroz E. Prevalence of sexually transmitted diseases in high-risk women in the Republic of Panama. Sex Transm Dis , 1987, 14(2): 69-74.
2.	Morrison EA, Ho GY, Vermund SH, et al . Human papillomavirus infection and other risk factors for cervical neoplasia: case-control study. Int J Cancer , 1991, 49(1): 6-13.
3.	Bosch FX, Muñoz N, de Sanjosé S, et al . Risk factors for cervical cancer in Colombia and Spain. Int J Cance r, 1992, 52(5): 750-758.
4.	Bosch FX, Manos MM, Muñoz N, et al . Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst , 1995, 87(11): 796-802.
5.	Yamakawa Y, Forslund O, Teshima H, et al . Human papillomavirus DNA in adenocarcinoma and adenosquamous carcinoma of the uterine cervix detected by polymerase chain reaction (PCR). Gynecol Oncol , 1994, 53(2): 190-195.
6.	Blumenthal PD, Gaffikin L, Chirenje ZM, et al . Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int J Gynaecol Obstet , 2001, 72(1): 47-53.
7.	Costa S, SideriM, Syrjanen K, et al . Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer. Acta Cytol , 2000, 44(3): 310-318.
8.	Cuzick J, Szarewski A, Terry G, et al . Human papillomavirus testing in primary cervical screening. Lancet , 1995, 345(8964): 1533-1536.
9.	Sherman ME, Lorincz AT, Scott DR, et al . Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst , 2003, 95(1), 46-52.
10.	Wu D, Ding L, Wu JH, et al . Application of liquid-based cytology and high-risk human papillomavirus DNA detection in cervical lesion screening. J South Med Nniv , 2007, 27(9): 1421-1423.
11.	Arbyn M, Buntinx F, Van Ranst M, et al . Cytologic versus virologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst , 2004, 96(4): 280-293.
12.	Solomon D, Schiffman M. Have we resolved how to triage equivocal cervical cytology? J Natl Cancer Inst , 2004, 96(4): 250-251.
13.	Paraskevaidis E, Arbyn M, Sotiriadis A, et al . The role of HPV testing in the follow up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev , 2004, 30(2): 205-211.
14.	Arbyn M, Paraskevaidis E, Martin-Hirsch P, et al . Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. Gynecol Oncol , 2005, 99(Suppl 3): 7-11.
15.	Solomon D, Davey D, Kurman R, et al . The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA , 2002, 287(16): 2114-2119.
16.	Richart RM. Cervical intraepithelial neoplasia. Pathol Annu , 1973, 8: 301-328.
17.	de Vet HCW, Eisinga A, Riphagen II, et al . Searching for studies//Deeks JJ, Bossuyt PM, Gatsonis C. Cochrane Handbook for Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration 2008. Available from: URL: http://srdta.cochrane.org.
18.	Smidt N, Deeks J, Moore T. Guide to the contents of a Cochrane review and protocol for Diagnostic Test Accuracy version 1.0.1 (updated February 2008). The Conchrane Collaboration 2008. Available from: URL: http://srdta.cochrane.org.
19.	Whiting P, Rutjes AW, Reitsma JB, et al . The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003. Available from: URL: http://www.biomedcentral.com/1471-2288/3/25.
20.	Whiting PF, Weswood ME, Rutjes AW, et al . Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006. Available from: URL: http://www.biomedcentral.com/1471-2288/6/9.
21.	Cochran WG. The combination of estimates from different experiments. Biometrics , 1954, 10(6): 101-129.
22.	Higgins JP, Thompson SG, Deeks JJ, et al . Measuring inconsistency in meta-analyses. BMJ , 2003, 327(7414): 557-560.
23.	Lytwyn A, Sellors JW, Mahony JB, et al . Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. CMAJ , 2000, 163(6): 701-707.
24.	Lytwyn A, Sellors JW, Mahony JB, et al . Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation. Arch Pathol Lab Med , 2003, 127(9): 1169-1175.
25.	Sankaranarayanan R, Nene BM, Dinshaw KA, et al . A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer , 2005, 116(4): 617-623.
26.	Kotaniemi-Talonen L, Nieminen P, Anttila1 A, et al . Cervical screening with primary HPV testing and cytology triage protocol in a randomized setting. British Journal of Cancer , 2005, 93(8): 862-867.
27.	Kotaniemi-Talonen L, Anttila A, Malila N, et al . Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer , 2008, 44(4): 565-571.
28.	Ronco G, Giorgi-Rossi P, Carozzi F, et al . Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst , 2008, 100(7): 492-501.
29.	Bjerre P, Silfverdal L, Dillner L, et al . A randomized trial of basing treatment on human papillomavirus and/or cytology results in low-grade cervical lesion triage. Am J Obstet Gynecol , 2008, 199(1): 24.e1-7.
30.	Giorgi-Rossi P, Segnan N, Zappa M, et al . The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective. Int J Cancer , 2007, 121(12): 2729-2734.
31.	Ronco G, Segnan N, Giorgi-Rossi P, et al . Human Papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst , 2006, 98(11): 765-774.
32.	Giorgi-Rossi P, Segnan N, Zappa M, et al . The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomized controlled trial from a public health perspective. Int J Cancer , 2007, 121(12): 2729-2734.
33.	Disaia PJ, Creasman WT. Preinvasive disease of the cervix. Disaia PJCreasman WT editor. Clinical gynecologic oncology. 6th ed. Health Science Asia, Elsevier Science, 2002: 1-33.
34.	Edward E, Abu-Rustum N, Susan M, et al . Cervical Cancer Screening. V.1.2010. NCCN Clinical Practice Guidelines in Oncology. Available from: URL: http://www.nccn.org.
35.	Kitchener HC, Almonte M, Thomson C. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomized controlled trial. Lancet Oncol , 2009, 10(7): 672-682.
36.	Kitchener HC, Almonte M, Gilham C. ARTISTIC: a randomised trial of human papillomavirus (HPV)testing in primary cervical screening. Health Technol Assess , 2009, 13(51): 1-150, iii-iv.

1. 1 Reeves WC, Quiroz E. Prevalence of sexually transmitted diseases in high-risk women in the Republic of Panama. Sex Transm Dis , 1987, 14(2): 69-74.
2. Morrison EA, Ho GY, Vermund SH, et al . Human papillomavirus infection and other risk factors for cervical neoplasia: case-control study. Int J Cancer , 1991, 49(1): 6-13.
3. Bosch FX, Muñoz N, de Sanjosé S, et al . Risk factors for cervical cancer in Colombia and Spain. Int J Cance r, 1992, 52(5): 750-758.
4. Bosch FX, Manos MM, Muñoz N, et al . Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst , 1995, 87(11): 796-802.
5. Yamakawa Y, Forslund O, Teshima H, et al . Human papillomavirus DNA in adenocarcinoma and adenosquamous carcinoma of the uterine cervix detected by polymerase chain reaction (PCR). Gynecol Oncol , 1994, 53(2): 190-195.
6. Blumenthal PD, Gaffikin L, Chirenje ZM, et al . Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int J Gynaecol Obstet , 2001, 72(1): 47-53.
7. Costa S, SideriM, Syrjanen K, et al . Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer. Acta Cytol , 2000, 44(3): 310-318.
8. Cuzick J, Szarewski A, Terry G, et al . Human papillomavirus testing in primary cervical screening. Lancet , 1995, 345(8964): 1533-1536.
9. Sherman ME, Lorincz AT, Scott DR, et al . Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst , 2003, 95(1), 46-52.
10. Wu D, Ding L, Wu JH, et al . Application of liquid-based cytology and high-risk human papillomavirus DNA detection in cervical lesion screening. J South Med Nniv , 2007, 27(9): 1421-1423.
11. Arbyn M, Buntinx F, Van Ranst M, et al . Cytologic versus virologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst , 2004, 96(4): 280-293.
12. Solomon D, Schiffman M. Have we resolved how to triage equivocal cervical cytology? J Natl Cancer Inst , 2004, 96(4): 250-251.
13. Paraskevaidis E, Arbyn M, Sotiriadis A, et al . The role of HPV testing in the follow up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev , 2004, 30(2): 205-211.
14. Arbyn M, Paraskevaidis E, Martin-Hirsch P, et al . Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. Gynecol Oncol , 2005, 99(Suppl 3): 7-11.
15. Solomon D, Davey D, Kurman R, et al . The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA , 2002, 287(16): 2114-2119.
16. Richart RM. Cervical intraepithelial neoplasia. Pathol Annu , 1973, 8: 301-328.
17. de Vet HCW, Eisinga A, Riphagen II, et al . Searching for studies//Deeks JJ, Bossuyt PM, Gatsonis C. Cochrane Handbook for Diagnostic Test Accuracy Version 1.0.0. The Cochrane Collaboration 2008. Available from: URL: http://srdta.cochrane.org.
18. Smidt N, Deeks J, Moore T. Guide to the contents of a Cochrane review and protocol for Diagnostic Test Accuracy version 1.0.1 (updated February 2008). The Conchrane Collaboration 2008. Available from: URL: http://srdta.cochrane.org.
19. Whiting P, Rutjes AW, Reitsma JB, et al . The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003. Available from: URL: http://www.biomedcentral.com/1471-2288/3/25.
20. Whiting PF, Weswood ME, Rutjes AW, et al . Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006. Available from: URL: http://www.biomedcentral.com/1471-2288/6/9.
21. Cochran WG. The combination of estimates from different experiments. Biometrics , 1954, 10(6): 101-129.
22. Higgins JP, Thompson SG, Deeks JJ, et al . Measuring inconsistency in meta-analyses. BMJ , 2003, 327(7414): 557-560.
23. Lytwyn A, Sellors JW, Mahony JB, et al . Comparison of human papillomavirus DNA testing and repeat Papanicolaou test in women with low-grade cervical cytologic abnormalities: a randomized trial. CMAJ , 2000, 163(6): 701-707.
24. Lytwyn A, Sellors JW, Mahony JB, et al . Adjunctive human papillomavirus testing in the 2-year follow-up of women with low-grade cervical cytologic abnormalities: a randomized trial and economic evaluation. Arch Pathol Lab Med , 2003, 127(9): 1169-1175.
25. Sankaranarayanan R, Nene BM, Dinshaw KA, et al . A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int J Cancer , 2005, 116(4): 617-623.
26. Kotaniemi-Talonen L, Nieminen P, Anttila1 A, et al . Cervical screening with primary HPV testing and cytology triage protocol in a randomized setting. British Journal of Cancer , 2005, 93(8): 862-867.
27. Kotaniemi-Talonen L, Anttila A, Malila N, et al . Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer , 2008, 44(4): 565-571.
28. Ronco G, Giorgi-Rossi P, Carozzi F, et al . Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst , 2008, 100(7): 492-501.
29. Bjerre P, Silfverdal L, Dillner L, et al . A randomized trial of basing treatment on human papillomavirus and/or cytology results in low-grade cervical lesion triage. Am J Obstet Gynecol , 2008, 199(1): 24.e1-7.
30. Giorgi-Rossi P, Segnan N, Zappa M, et al . The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective. Int J Cancer , 2007, 121(12): 2729-2734.
31. Ronco G, Segnan N, Giorgi-Rossi P, et al . Human Papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst , 2006, 98(11): 765-774.
32. Giorgi-Rossi P, Segnan N, Zappa M, et al . The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomized controlled trial from a public health perspective. Int J Cancer , 2007, 121(12): 2729-2734.
33. Disaia PJ, Creasman WT. Preinvasive disease of the cervix. Disaia PJCreasman WT editor. Clinical gynecologic oncology. 6th ed. Health Science Asia, Elsevier Science, 2002: 1-33.
34. Edward E, Abu-Rustum N, Susan M, et al . Cervical Cancer Screening. V.1.2010. NCCN Clinical Practice Guidelines in Oncology. Available from: URL: http://www.nccn.org.
35. Kitchener HC, Almonte M, Thomson C. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomized controlled trial. Lancet Oncol , 2009, 10(7): 672-682.
36. Kitchener HC, Almonte M, Gilham C. ARTISTIC: a randomised trial of human papillomavirus (HPV)testing in primary cervical screening. Health Technol Assess , 2009, 13(51): 1-150, iii-iv.

上一篇
患者参与患者安全的系统评价
下一篇
通心络胶囊与丹参滴丸治疗冠心病心绞痛间接比较的系统评价

《中国循证医学杂志》

人类乳头状病毒检测诊断宫颈癌前病变的价值：随机对照研究的系统评价

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

《中国循证医学杂志》

人类乳头状病毒检测诊断宫颈癌前病变的价值：随机对照研究的系统评价

摘要 全文 图表 视频 参考文献 施引文献 补充材料

上一篇

下一篇

Format

Content

摘要全文图表视频参考文献施引文献补充材料